Clinical Trial Update: Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma [Phase 4]

View source ↗

Summary

Clinical trial update for consolidation with axicabtagene ciloleucel after first-line treatment in high-risk diffuse large B-cell lymphoma (Phase 4, recruiting)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Sponsor: Zhengzhou University | Conditions: Lymphoma, B-Cell | Phase 4 | Status: RECRUITING